Multicenter Trial Management Unit Expands the Scope of Research at Yale
In the past, Yale investigators who led multicenter trials had to put together ad hoc study teams, relying on unconnected siloed services to carry out their research. At the end of these trials, these teams, which had compiled so much experience and knowledge, disbanded and their knowledge was lost. This system was inefficient and put Yale at a disadvantage when competing with other institutions for grants for multicenter studies.
WHRY Funds Studies on Stroke, Endometrial Cancer, and Addiction to Opioids
Women’s Health Research at Yale today announced funding for three studies investigating sex differences in stroke, endometrial cancer, and alternate pain relief for women recovering from past opioid use who are giving birth via cesarean section.
Deadlier Colon Cancer Develops Differently in Women and Men
WHRY-affiliated researchers have found that colon cancer tumor cells produce energy for growth differently in women and men, and that this difference is associated with a more aggressive form of tumor growth with a higher incidence in women.
Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
Throat Cancers Are on the Rise: Why This Matters to You
These cancers are on the rise among men, and HPV is causing the uptick. The Centers for Disease Control and Prevention (CDC) estimates that 79 million Americans are infected with HPV and that 90% of men and 80% of women will be infected with the virus at some point in their lives.Source: Yale Medicine
Humanized Mice Lead to Breakthroughs in Blood Cancers
Humanized mice created at Yale are opening new avenues of research into cancers caused by disorders in the production of blood, such as acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Until recently, such research was hindered because human blood stem cells are difficult to grow in cell cultures or to engraft in mice.
Dark Chemical Matter and Colon Cancer
Seven years ago, Jason Crawford, PhD, began chasing a ghost: A bacterial toxin named colibactin. He was looking for its molecular structure. He could detect bits of it, but never enough to form an entire likeness. Four years into the hunt he asked Seth Herzon, PhD, to join him. They pursued colibactin so doggedly because it is associated with up to 67 percent of all colon cancers.
The Microbiome and Cancer Treatment
Andrew Goodman, PhD, studies the abundant flora in the gut, but he initially trained in ecology and sees many parallels. He thinks of the microbiome as an ecosystem and the members of the ecosystem as bacteria. His recent research reveals that microbes are dynamic agents that should be considered in medical care.
Cancer and Obesity: The Link is Insulin
Nearly 40 percent of Americans over the age of 20 are obese, and another 32 percent are overweight. These alarming figures grow darker when combined with statistics showing that obesity is second only to smoking as a cause of preventable cancer deaths. Obesity has been linked to more than a dozen types of cancer.
From Paradox to Breakthrough
Aaron Ring, MD, PhD, was hooked by a paradox. He had been studying cytokines to understand their potential to stimulate anti-tumor immunity. Though cytokines, such as interleukin-2, have been in clinical use for decades, they have historically shown only limited effectiveness. Dr. Ring was hunting for interleukins that could deliver a specific signal to activate TILs.
Ten Years of Leadership in Immunotherapy
The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest breakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.
Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers'
A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as “drivers” — variations in DNA sequences that lead to the development of cancer.
Kunz Named Leader of Gastrointestinal Cancers Program at Smilow Cancer Hospital and Yale Cancer Center
Pamela L. Kunz, M.D., has been appointed Leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center and Director of GI Medical Oncology within the Section of Medical Oncology.